Pipeline Therapeutics Funding: $110M Raised, Series C (2021)
Pipeline Therapeutics is based in San Diego, California. It has raised $110M in total funding. Latest round: Series C.
Pipeline Therapeutics funding overview
Pipeline Therapeutics is based in San Diego, California. Pipeline Therapeutics has raised $110M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series C announced in February 2021. The round record for Pipeline Therapeutics runs through 2021; nothing later has been disclosed. Investors on record include Versant Ventures, Sectoral Asset Management, Cleva Pharma Capital, RBV Capital, Hadean Ventures, Perceptive Advisors and 5 others. 11 distinct backers are named across the disclosed rounds.
Pipeline Therapeutics at a glance
Total raised
$110M
Latest round
Series C
Latest round date
February 2021
Headquarters
San Diego, California
Notable investors
Versant Ventures, Sectoral Asset Management, Cleva Pharma Capital, RBV Capital, Hadean Ventures, Perceptive Advisors, Franklin Templeton, Casdin Capital
Frequently asked about Pipeline Therapeutics funding
How much has Pipeline Therapeutics raised?
Pipeline Therapeutics has raised $110M in total disclosed funding across the rounds on record.
Who has invested in Pipeline Therapeutics?
Versant Ventures, Sectoral Asset Management, Cleva Pharma Capital, RBV Capital, Hadean Ventures, Perceptive Advisors are named among the investors backing Pipeline Therapeutics.
What was the latest Pipeline Therapeutics funding round?
The most recent disclosed round is a Series C, announced in February 2021.
Where is Pipeline Therapeutics based?
Pipeline Therapeutics is based in San Diego, California.
When did Pipeline Therapeutics last raise?
The last disclosed Pipeline Therapeutics round closed in February 2021 at Series C.
Pipeline Therapeutics totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in San Diego below to benchmark round size and investor mix.
